With 2023 marking a significant global market slowdown, many IPO candidates have suspended or postponed their plan. Only six initial public offerings (IPOs) have been successful in.
Completion of the additional equity investment of $140M by AstraZeneca, as previously announced on November 1 and 15, 2023 NEW YORK, May 06, 2024 Cellectis a clinical-stage biotechnology.